New River Pharmaceuticals Inc. could receive $500 million in a collaboration deal with Shire Pharmaceuticals Group plc for global commercialization of New River's Phase III compound being developed for attention deficit hyperactivity disorder. (BioWorld Today)

New River Pharmaceuticals Inc. could receive $500 million in a collaboration deal with Shire Pharmaceuticals Group plc for global commercialization of New River's Phase III compound being developed for attention deficit hyperactivity disorder. (BioWorld Today)